fbpx

Studies

Join a study.
Help find a cure.

Every medical breakthrough we celebrate and benefit from is because of volunteers just like you. Everyday people who say “yes” to participating in clinical trials are changing the world for the better.

Explore our open studies — each one represents an opportunity to help build healthier futures.

studies

Select a condition
to view the relevant open studies

Filter by Condition
Additional Filters

“AHEAD” Alzheimer’s Prevention

If you're worried that your memory might start fading, then joining an Alzheimer's prevention study might be a great option for you. It might just help future generations too. This study examines whether a new drug may help to slow or prevent the onset of Alzheimer's disease in those with elevated risk of developing the disease.

Preliminary Qualifications

  • 55-80 years of age.
  • Normal memory and thinking.
  • Have not been diagnosed with Alzheimer’s disease.

AriBio Early Alzheimer’s Trial

The purpose of this study is to find out if the study drug, called AR1001, can help people with Alzheimer’s Disease. Some research has shown that people with Alzheimer’s Disease have damage to the blood vessels in their brain. It is thought that AR1001 may help the blood vessels in your brain work better.

Preliminary Qualifications

  • 55-80 years of age.
  • Mild cognitive impairment or mild dementia consistent with Alzheimer's disease.
  • A history of subjective memory decline with gradual onset in the last 3 years.

“Signal-C” Colorectal Cancer Test

We are validating Signal-C®, a blood-based diagnostic test to screen for colorectal cancer, in hopes this innovative new test may one day indicate if you need further evaluation.

Preliminary Qualifications

  • 45-84 years of age
  • Have, or will have, an upcoming colonoscopy.
  • Considered by a physician or healthcare provider as being of 'average risk' for colorectcal cancer
  • Willing to consent to blood draw prior to bowel preparation and undergoing colonoscopy

GAP “Apheleia” Alzheimer’s Identification Study

This short study aims to identify and characterize participants with reported cognitive impairment using demographic information, clinical history, brief cognitive assessments, and a blood test to distinguish appropriate participants for referral to a therapeutic Alzheimer's clinical trial.

Preliminary Qualifications

  • 50-90 years of age.
  • Progressive cognitive complaints must be reported by participant or caregiver.
  • Interest in participating in clinical research.

Altimmune NASH Study

This study is for people with a diagnosis of non-alcoholic steatohepatitis (NASH), which is a condition that causes liver inflammation and damage due to a buildup of fat in the liver. The investigational drug, pemvidutide, is being developed as a possible treatment for NASH.

Preliminary Qualifications

  • 18-75 years of age.
  • Diagnosis of NASH.
  • BMI greater than or equal to 27.

“Cerevel 004” Parkinson’s Disease Open-Label Trial

This study is "open label", which means all participants will receive the study medication. We're testing an oral medication called Tavapadon as a possible treatment for Parkinson's disease over 62-66 weeks. Tavapadon aims to improve motor control symptoms.

Preliminary Qualifications

  • 40-80 years of age.
  • Have been diagnosed with Parkinson's disease within the last 3 years.

“Cohort” Alzheimer’s Study

The goal of this study is to build a large group, or “cohort”, of individuals who are interested in being recruited into Alzheimer's dementia clinical trials. We will collect data from cognitively normal or minimally-impaired individuals and then inform them if a trial may be appropriate.

Preliminary Qualifications

  • 50-85 years of age.
  • In good general health.

Tau Protein “PET” Detection Study

The purpose of this study is to investigate the effectiveness and safety of a new injection—given in conjunction with a PET scan—to help detect tau protein in the brain. Early detection could help with the diagnostic process, as well as the treatment of, Alzheimer's disease.

Preliminary Qualifications

  • 50+ years of age.
  • A projected life expectancy of less than or equal to 1 year.
  • Study includes brain scan (PET scan).

Amyloid Plaque “AbbVie” Alzheimer’s Study

Amyloid plaques in the brain may be the main cause of Alzheimer's disease. This study is to determine if a new drug can reduce amyloid plaques and slow disease progression.

Preliminary Qualifications

  • 50-90 years of age.
  • Diagnosis of mild-to-moderate Alzheimer's disease.

Sensory Stimulation Alzheimer’s “Hope” Study

The main purpose of this study is to see whether daily use of a device called the "Sensory Stimulation System" can help people with Alzheimer's-related memory problems. The device provides sensory stimulation via glasses worn on the face and headphones worn over the ears.

Preliminary Qualifications

  • 50-85 years of age.
  • Diagnosis of mild-to-moderate Alzheimer's disease.

Obesity “Triumph-3” Study

Obesity is a complex disease with many underlying causes and impacts on health. This study is to test a new drug with the potential to deliver substantial body weight reduction across the spectrum of obesity.

Preliminary Qualifications

  • Must be at least 18 years of age.
  • BMI greater than 35.

Essential Tremor “Sage” Study

This study involves a drug which is being evaluated in the treatment of essential tremor, to determine if the drug reduces tremor in the arm and whether it might have other effects on essential tremor symptoms.

Preliminary Qualifications

  • 18 to 80 years of age.
  • Diagnosis of essential tremor.

Essential Tremor “Botox” Study

The purpose of this study is to see if the study drug is safe and helps to reduce upper limb essential tremor in adults who experienced persistent, bilateral tremor during movement, involving hands and forearms.

Preliminary Qualifications

  • 18 to 80 years of age.
  • Diagnosis of essential tremor.

“Avanir” Alzheimer’s Agitation Trial

This study evaluates a new medication to treat agitation in people with Alzheimer's disease. It is hoped this potential treatment could reduce caregiver burden and improve overall disease prognosis.

Preliminary Qualifications

  • 50-90 years of age.
  • Sometimes experience feelings of agitation.
  • Diagnosis of Alzheimer’s disease.

Protein Inhibitor “Annovis” Alzheimer’s Study

A research study of a drug called buntanetap under development for the treatment of Alzheimer’s disease, possibly improving cognition in patients by inhibiting neurotoxic proteins.

Preliminary Qualifications

  • Diagnosis of Alzheimer's disease.
  • 55-85 years of age.

“CELIA” Alzheimer’s Trial

This study tests a new investigational medication for the treatment of Alzheimer's disease.  The drug is hoped to work by targeting and preventing the accumulation of tau tangles.

Preliminary Qualifications

  • 50-80 years of age.
  • Have mild cognitive impairment due to Alzheimer's disease, or mild Alzheimer's disease.

Combination Therapy “CuraSen” Trial

The goal of the study is to evaluate the effects of a novel combination therapy on cognition and mood in patients with mild cognitive impairment or mild dementia due to either Parkinson’s or Alzheimer’s disease.

Preliminary Qualifications

  • 50-85 years of age.
  • Diagnosis of mild cognitive impairment or mild dementia due to either Parkinson's disease or Alzheimer's disease.

Combination Therapy “CuraSen” Trial

The goal of the study is to evaluate the effects of a novel combination therapy on cognition and mood in patients with mild cognitive impairment or mild dementia due to either Parkinson’s or Alzheimer’s disease.

Preliminary Qualifications

  • 50-85 years of age.
  • Diagnosis of mild cognitive impairment or mild dementia due to either Parkinson's Disease or Alzheimer's Disease.

“Merck” Early Alzheimer’s Disease Trial

In this trial, an investigational drug is used to target tau proteins to reduce or stop their spread and slow the progression of Alzheimer's disease.

Preliminary Qualifications

  • 50-80 years of age.
  • Have mild cognitive impairment due to Alzheimer's disease, or mild or moderate Alzheimer's disease.

“Cerevel 002” Parkinson’s Disease Trial

We're testing an oral medication called Tavapadon as a possible treatment for Parkinson's disease over 35 weeks. Tavapadon aims to improve motor control symptoms.

Preliminary Qualifications

  • 40-80 years of age.
  • Have been diagnosed with Parkinson's disease within the last 3 years.

Dementia with Lewy Bodies “Shimmer” Study

This study looks at a new investigational medication to see if it will slow cognitive decline in individuals with Dementia with Lewy Bodies. The drug has been previously studied in 3 completed clinical trials and in 4 ongoing trials.

Preliminary Qualifications

  • 50-85 years of age.
  • Have a diagnosis of Dementia with Lewy Bodies.

“ENVISION” Alzheimer’s Trial

This study tests the FDA-approved medication Aduhelm. The trial is designed to verify the drug's efficacy in reducing amyloid plaques and slowing the rate of cognitive decline.

Preliminary Qualifications

  • 60-85 years of age.
  • Have experienced a progression of cognitive decline for 6 months or more.

“Precision” NASH Trial

This quick study is to collect blood samples from people with various stages of fatty liver disease or NASH to support advancements in medical diagnoses of diseases such as fatty liver disease and NASH.

Preliminary Qualifications

  • 18 years of age or older.

Register for a Prescreen

Sign up for an initial assessment (called a “prescreen”), and we'll give you a call. One of our professional medical staff will answer your questions and give you more information about Charter Research prior to an in-office visit.

Sign Up Now

Your contact information

Do you live in Central Florida?

Preferred Charter Research location

I would like to receive the Charter Research newsletter.

Comments (not required)

This field is for validation purposes and should be left unchanged.